Abstract
Loperamide (R 18 553) was compared with placebo in a double-blind crossover study of 21 patients with chronic diarrhea caused by ileocolic disease or resection. Patients (18) completed the trial. At a median daily dose of 6 mg the new antidiarrheal preparation was superior to placebo in controlling chronic diarrhea. Frequency and weight of stools significantly decreased, the stools became more solid, and carmine transit time was prolonged during loperamide therapy. Loperamide was consistently preferred to placebo by patients. Gastrointestinal side-effects were few and comparable during both treatment periods.

This publication has 16 references indexed in Scilit: